Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NLRP3 | Q96P20 | 7/20 | 0.53 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.53 |
| ▸ | IL1B | P01584 | 9/20 | 0.42 |
| ▸ | TNF | P01375 | 2/20 | 0.42 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.39 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.39 |
| ▸ | CDK4 | P11802 | 4/20 | 0.36 |
| ▸ | CCND1 | P24385 | 4/20 | 0.36 |
| ▸ | CCND3 | P30281 | 4/20 | 0.36 |
| ▸ | CDK6 | Q00534 | 4/20 | 0.36 |
| ▸ | CCR2 | P41597 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29326425 | 0.92 | NLRP3 (0.53) | NLRP3KCNH2IL1BTNFTMEM97 | |
| SCHEMBL29326402 | 0.91 | NLRP3 (0.51) | NLRP3KCNH2IL1BTNF | |
| SCHEMBL29326732 | 0.88 | NLRP3 (0.48) | NLRP3KCNH2IL1BTNFTMEM97 | |
| SCHEMBL29326535 | 0.87 | CDK4 (0.38) | NLRP3KCNH2CDK4CCND1CCND3 | |
| SCHEMBL24696096 | 0.86 | NLRP3 (0.71) | NLRP3KCNH2IL1BTNF | |
| SCHEMBL29326491 | 0.86 | NLRP3 (0.71) | NLRP3KCNH2IL1BTNF | |
| SCHEMBL29326421 | 0.86 | NLRP3 (0.71) | NLRP3KCNH2IL1BTNF | |
| SCHEMBL29326357 | 0.86 | NLRP3 (0.68) | NLRP3KCNH2IL1BTNF | |
| SCHEMBL29326492 | 0.86 | NLRP3 (0.71) | NLRP3KCNH2IL1BTNF | |
| SCHEMBL29975000 | 0.86 | NLRP3 (0.71) | NLRP3KCNH2IL1BTNF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240239758-A1 | SUBSTITUTED TRIAZINE COMPOUND | NICO THERAPEUTICS, INC. | 2024-07-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240239758-A1 | SUBSTITUTED TRIAZINE COMPOUND | NLRP3, NLRP1, PYCARD | NLRP3 1/4885KCNH2 2120/4885IL1B 11/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.